Arca
Skip to content
Tools
Tools

Sickle cell anemia

Drug research and approvals for sickle cell anemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 162 studies of sickle cell anemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 4 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 162
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 4
  • EU medicines: 0

Recruiting now

Newest posted first, of 162 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 7

Phase 3 12 of 19

Phase 2 12 of 70

Phase 1 or earlier 12 of 44

How its trials ended

1,021 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 247 whose ending is known, 28% met their primary endpoint, 9% missed it and 63% stopped early.

  • Completed, result not reported42842%
  • Ongoing27927%
  • Stopped: other or unclear737%
  • Met its primary endpoint697%
  • Status unknown677%
  • Stopped: enrollment or feasibility465%
  • Missed its primary endpoint222%
  • Stopped: sponsor or business decision151%
  • Stopped: lack of efficacy121%
  • Stopped: funding91%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Dec 9, 2025A phase 2/3 randomized, multicenter study of osivelotor administered orally to adult and adolescent participants with sickle cell diseaseOsivelotor (PF-07940367, GBT021601)PfizerPending
May 22, 2024Optima study : optimizing hydroxyurea dosage with pharmakokinetic in patients suffering of moderate to severe sickle cell anemia.HydroxyureaDr. Yves PastoreOngoing
Jun 4, 2018A vitamin D intervention in children with sickle cell disease: a pilot randomised controlled trialVitamin DChu Sainte JustineOngoing
Apr 20, 2018A randomised, double-blind, parallel-group, multicentre, phase III study to evaluate the effect of ticagrelor versus placebo in reducing the rate of…Brilinta (ticagrelor)AstraZeneca PharmaceuticalsClosed
Nov 25, 2016A multiple-dose, subject-and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885…ACZ885 (canakinumab)Novartis PharmaceuticalsClosed
Apr 24, 2013A phase 3, double-blind, randomized, efficacy and safety comparison of prasugrel and placebo in pediatric patients with sickle cell diseasePrasugrel (LY640315)Eli LillyOngoing
Apr 2, 2013The pharmacokinetic profile of a single dose of ferriprox® in patients with sickle cell diseaseDeferiproneApopharma IncClosed

FDA orphan designations

Approved first, then open designations, newest first
Dec 23, 2024XromiTo reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients 6 months of age and older with…Nova Laboratories LimitedApproved
Apr 4, 2024XromiTo reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age to less…Nova Laboratories LimitedApproved
Dec 21, 2017SiklosTo reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older,…Theravia PharmaApproved
Feb 25, 1998DroxiaTo reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with…Bristol-Myers Squibb Pharmaceutical Research InstituteApproved
Apr 15, 2005HydroxyureaTreatment of pediatric patients with sickle cell anemia.UPM Pharmaceuticals, Inc.Designated
May 7, 1999Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda…Prevention of transient aplastic crisis in patients with sickle cell anemia.MedImmune, Inc.Designated
Dec 21, 1998Deferoxamine starch conjugateTreatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.Biomedical Frontiers, Inc.Designated
Mar 25, 1992Polymeric oxygenTreatment of sickle cell anemia.Capmed USADesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.